Format

Send to

Choose Destination
Curr Opin Mol Ther. 2005 Aug;7(4):394-401.

Technology evaluation: huN901-DM1, ImmunoGen.

Author information

1
Australian Nuclear Science and Technology Organisation (ANSTO), Institute of Materials Engineering and Science, Menai, NSW 2234, Australia. svs@ansto.gov.au

Abstract

ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer.

PMID:
16121706
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center